Cintia Piccina Sells 24,531 Shares of Adaptimmune Therapeutics plc (NASDAQ:ADAP) Stock

Adaptimmune Therapeutics plc (NASDAQ:ADAPGet Free Report) insider Cintia Piccina sold 24,531 shares of Adaptimmune Therapeutics stock in a transaction dated Tuesday, June 18th. The stock was sold at an average price of $0.93, for a total transaction of $22,813.83. Following the transaction, the insider now directly owns 38,293 shares of the company’s stock, valued at $35,612.49. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

Adaptimmune Therapeutics Stock Down 0.8 %

Adaptimmune Therapeutics stock opened at $0.87 on Friday. The firm has a market cap of $215.42 million, a P/E ratio of -1.18 and a beta of 2.33. The business has a fifty day moving average of $1.07 and a two-hundred day moving average of $1.07. Adaptimmune Therapeutics plc has a twelve month low of $0.42 and a twelve month high of $2.05.

Adaptimmune Therapeutics (NASDAQ:ADAPGet Free Report) last issued its quarterly earnings data on Wednesday, May 15th. The biotechnology company reported ($0.18) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.02). Adaptimmune Therapeutics had a negative return on equity of 259.68% and a negative net margin of 890.13%. The company had revenue of $5.68 million for the quarter, compared to analysts’ expectations of $4.40 million. Equities analysts expect that Adaptimmune Therapeutics plc will post -0.66 earnings per share for the current year.

Institutional Trading of Adaptimmune Therapeutics

Hedge funds have recently modified their holdings of the company. Boulder Hill Capital Management LP purchased a new position in shares of Adaptimmune Therapeutics in the 1st quarter worth approximately $143,000. Twin Focus Capital Partners LLC purchased a new position in Adaptimmune Therapeutics in the fourth quarter worth $44,000. JTC Employer Solutions Trustee Ltd acquired a new position in shares of Adaptimmune Therapeutics during the first quarter worth $41,000. Key Client Fiduciary Advisors LLC lifted its holdings in shares of Adaptimmune Therapeutics by 6.4% during the 4th quarter. Key Client Fiduciary Advisors LLC now owns 336,620 shares of the biotechnology company’s stock valued at $267,000 after purchasing an additional 20,295 shares during the last quarter. Finally, Columbia Advisory Partners LLC acquired a new stake in shares of Adaptimmune Therapeutics in the 1st quarter worth $25,000. 31.37% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several analysts have issued reports on the stock. Mizuho decreased their price objective on shares of Adaptimmune Therapeutics from $9.00 to $3.00 and set a “buy” rating for the company in a research note on Friday, May 17th. StockNews.com upgraded Adaptimmune Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, June 3rd. Finally, Scotiabank started coverage on Adaptimmune Therapeutics in a research note on Thursday, May 30th. They issued a “sector outperform” rating and a $3.15 target price on the stock.

Read Our Latest Stock Analysis on Adaptimmune Therapeutics

About Adaptimmune Therapeutics

(Get Free Report)

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.

Recommended Stories

Insider Buying and Selling by Quarter for Adaptimmune Therapeutics (NASDAQ:ADAP)

Receive News & Ratings for Adaptimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.